206 related articles for article (PubMed ID: 30874447)
1. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
[No Abstract] [Full Text] [Related]
2. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
3. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
4. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP
Ann Am Thorac Soc; 2014 Mar; 11(3):342-50. PubMed ID: 24476418
[TBL] [Abstract][Full Text] [Related]
5. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
Nichols DP; Odem-Davis K; Cogen JD; Goss CH; Ren CL; Skalland M; Somayaji R; Heltshe SL
Am J Respir Crit Care Med; 2020 Feb; 201(4):430-437. PubMed ID: 31661302
[No Abstract] [Full Text] [Related]
7. Testing the effects of combining azithromycin with inhaled tobramycin for
Nichols DP; Singh PK; Baines A; Caverly LJ; Chmiel JF; GIbson RL; Lascano J; Morgan SJ; Retsch-Bogart G; Saiman L; Sadeghi H; Billings JL; Heltshe SL; Kirby S; Kong A; Nick JA; Mayer-Hamblett N;
Thorax; 2022 Jun; 77(6):581-588. PubMed ID: 34706982
[TBL] [Abstract][Full Text] [Related]
8. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Blumer JL; Saiman L; Konstan MW; Melnick D
Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
[TBL] [Abstract][Full Text] [Related]
10. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
11. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.
VanDyke RD; McPhail GL; Huang B; Fenchel MC; Amin RS; Carle AC; Chini BA; Seid M
Ann Am Thorac Soc; 2013 Jun; 10(3):205-12. PubMed ID: 23802816
[TBL] [Abstract][Full Text] [Related]
12. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
[TBL] [Abstract][Full Text] [Related]
13. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
[TBL] [Abstract][Full Text] [Related]
14. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
15. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
Nichols DP; Happoldt CL; Bratcher PE; Caceres SM; Chmiel JF; Malcolm KC; Saavedra MT; Saiman L; Taylor-Cousar JL; Nick JA
J Cyst Fibros; 2017 May; 16(3):358-366. PubMed ID: 28025037
[TBL] [Abstract][Full Text] [Related]
16. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
[TBL] [Abstract][Full Text] [Related]
19. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
20. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
